



## Confirmation of WHO Active Pharmaceutical Ingredient Prequalification (CPQ)

<b>Date:</b>	10 June 2016
<b>WHO prequalification number:</b>	WHOAPI-158
<b>Active pharmaceutical ingredient (API):</b>	Pyrazinamide
<b>API specification number:</b>	FPS/136-01 version 01
<b>Re-test Period:</b>	60 months
<b>Storage conditions</b>	Do not store above 30°C, protect from light

### API Manufacturers:

Anuh Pharma. Limited  
Manufacturing Block - NP-1  
E17/3 & 17/4 MIDC  
Tarapur, Biosar Thane – 401506  
Maharashtra  
India

### API Intermediate manufacturers: *(in addition to the API manufacturers above)*

Not applicable.

This is to confirm that Pyrazinamide, manufactured by Anuh Pharma Ltd, has been prequalified by the World Health Organization (WHO). Further information on the API prequalification procedure can be located on the Prequalification Team - Medicines Assessment web page:

[http://www.who.int/prequal/info\\_applicants/API\\_info\\_applicants.htm](http://www.who.int/prequal/info_applicants/API_info_applicants.htm).

API prequalification provides an assurance that the supplied API is of good quality. The comprehensive evaluation procedure has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards, and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements.

The decision to prequalify Pyrazinamide, manufactured by Anuh Pharma Ltd, is particular to the specific details assessed during evaluation, such as sites of manufacture, method of manufacture, control of the API and retest period.